James Tita, DO
Pulmonary Disease · Toledo, OHNPI 1811988579
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $199 and has fallen 84.1% since, to $32 in 2025. That places this record below the midpoint for pulmonary disease clinicians in OH, where the typical reported total is $1,293.
Across 34 payments — averaging $22.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$115
- Intuitive Surgical$98
- Inspire Medical Systems, Inc.$92
- AstraZeneca$73
- Takeda Pharmaceuticals U.S.A., Inc.$60
- Insmed, Inc.$59
- plus $257 from 12 others
Across 27 payments — averaging $11,439 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$246K
- Roche Products Limited$63K
What the payments were for
- Food & beverage$74098%
- Education$142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 4 | $115 |
| Intuitive Surgical | 1 | $98 |
| Inspire Medical Systems, Inc. | 1 | $92 |
| AstraZeneca(2 entities) | 5 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Insmed, Inc. | 4 | $59 |
| GSK | 3 | $52 |
| Baxter Healthcare | 1 | $37 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
| Grifols USA, LLC | 1 | $24 |
| La Jolla Pharmaceutical Company | 1 | $20 |
| Inogen, Inc. | 2 | $19 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| United Therapeutics Corporation | 1 | $3 |
How this compares
$754 in reported general payments places this provider in the 40th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 173 | $177,410 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 143 | $103,360 |
| NucalaMepolizumab | 26 | $93,578 |
| Dupixent SyringeDupilumab | 14 | $61,767 |
| Breo ElliptaFluticasone/Vilanterol | 80 | $57,418 |
| Spiriva RespimatTiotropium Bromide | 59 | $50,745 |
| Spiriva HandihalerTiotropium Bromide | 49 | $31,827 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 43 | $31,797 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 73 | $26,749 |
| EliquisApixaban | 16 | $24,861 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $22,805 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 597 | $21,583 |
| SymbicortBudesonide/Formoterol Fumarate | 47 | $20,738 |
| Incruse ElliptaUmeclidinium Bromide | 38 | $16,458 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 97 | $15,295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta, Incruse Ellipta | $52 | $448,224460 claims |
| AstraZenecaSymbicort | $73 | $20,73847 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Toledo
- Fateh AhmedToledo$49K
- Joseph KhabbazaAkron$655K
- Robert BaughmanCincinnati$640K
- Kristin HighlandCleveland$551K
- Bruce CorserCincinnati$502K
- Jason StieneckerLima$397K
- Mohammad SheattCincinnati$389K
- Mohammad KhanAkron$388K
- Thomas YungerDayton$353K
- Joseph CiceniaCleveland$350K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.